"It's not about what you can do, but about what you have inside"
EVIDENCE
THE EVIDENCE* STUDY
Overview of The EVIDENCE Study
Data from the EVIDENCE study shows that Rebif® (interferon beta 1-a) 44 mcg three times per week (tiw) works better than Avonex® (interferon beta 1-a) 30 mcg once a week (qw) at preventing relapses at 24 and 48 weeks. These results were seen in patients through the completion of the study — which was an average of 64 weeks.
- Meet the MS LifeLines Team
Take a video tour of MS LifeLines.
Mire este vídeo en español. -
- MTV
- Conozca al equipo de MS LifeLines
Realice un tour en video por MS LifeLines. -
- ES_MTV
- Rebif Injection Training Video
Mire este vídeo en español. -
- RITV
- Video de entrenamiento sobre la inyección de Rebif
-
- ES_RITV
- View How Rebif (interferon beta-1a) Works
Find out how Rebif can help slow the progression of your relapsing MS. -
- MOA
- Find new ways to accommodate your day-to-day needs. Watch other interviews
-
- Shiela_01
- What was the most compelling reason to choose Rebif for your relapsing MS therapy? Watch other interviews
-
- Juli
- Watch as Kellie talks about her MRI lesion load. Watch other interviews
-
- Kellie
- Shiela shares insights about communication with her daughter about MS. Watch other interviews
-
- Shiela
Patients in the EVIDENCE study were treated for an average of 64 weeks through the completion of the study:
- Studied the effects of Rebif given by subcutaneous (under the skin) injections at a dose of 44 mcg, three times per week (total weekly dose 132 mcg).
- Studied against Avonex given by intramuscular injection at a dose of 30 mcg, once a week (total weekly dose 30 mcg).
- Included 339 people taking Rebif and 338 taking Avonex.
People taking Rebif showed a significant reduction in MRI activity at 24 weeks, 48, and through the completion of the study at an average of 64 weeks.
- Patients treated with Rebif had fewer active lesions per MRI scan for all activity measures with effects seen within two to three months of starting treatment.
- More than half (58%) of Rebif patients had no new MRI lesions vs. 38% of patients on Avonex at 64 weeks.
- Rebif patients had one-third fewer active lesions compared with Avonex patients.
The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.
People taking Rebif 44 mcg tiw were more likely to remain relapse-free than people treated with Avonex 30 mcg qw. This was shown at 24, 48, and through the completion of the study at an average of 64 weeks:
- 75% of patients who received Rebif did not have a relapse after 24 weeks of treatment compared to 63% of patients treated with Avonex
Side effects were generally similar in those treated with Rebif compared to those treated with Avonex:
- People taking Rebif had a greater number of injection site reactions (85% Rebif vs. 33% Avonex), increased liver disorders (18% Rebif vs. 10% Avonex), and white blood cell disorders (13.6% Rebif vs. 5.3% Avonex).
- The majority of side effects for both products were mild and the number of serious side effects was low in both groups.
- Flu-like symptoms were significantly greater for people taking Avonex than people taking Rebif (53% Avonex vs. 45% Rebif).
Avonex is a registered trademark of Biogen Idec.
* EVidence for Interferon Dose-response: European North American Comparative Efficacy.
